Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma

Condition(s) studied

Investigational drug(s) / intervention(s)

Dynamometry measurement, myokine dosing, sarcopenia calculation: Blood sampling during standard pre-therapeutic care (at the same time with a standard blood testing) and dynamometry measurement. Retrieval of scanographic imaging and calculation of the L3 SMI index

Study summary

It is known that some substances present in the blood, called 'myokines,' influence muscle loss. Some may accelerate this loss, while others may prevent it. Inflammatory substances in the blood can also contribute to muscle loss. Sarcopenia is assessed by an imaging technique called 'Skeletal Muscle Mass Index (SMI)' to measure muscle mass. This analysis can be done from radiological examinations. Sarcopenia has a serious impact on patients with hepatocellular carcinoma. It increases the risk of death, cancer recurrence, and decreases the response to treatments. Therefore, the investigators want to determine if blood tests for myokines obtained by simple blood draw can improve the assessment of sarcopenia in this specific setting.

Eligibility

Primary outcome measure(s)

• Determine if serum myokines measured in patients with HCC are correlated with muscle mass index assessed by standard scanographic technique. — Day 1
  Analysis of correlation between serum myokines measured in patients with HCC and muscle mass index assessed by standard scanographic technique

Trial sites (1)

More CHU de Reims trials in France

Other trials for the same condition